Skip to content
lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
TScan Therapeutics, Inc.
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 12, 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026